265 related articles for article (PubMed ID: 12874005)
1. Transport of methotrexate, methotrexate polyglutamates, and 17beta-estradiol 17-(beta-D-glucuronide) by ABCG2: effects of acquired mutations at R482 on methotrexate transport.
Chen ZS; Robey RW; Belinsky MG; Shchaveleva I; Ren XQ; Sugimoto Y; Ross DD; Bates SE; Kruh GD
Cancer Res; 2003 Jul; 63(14):4048-54. PubMed ID: 12874005
[TBL] [Abstract][Full Text] [Related]
2. Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter.
Volk EL; Schneider E
Cancer Res; 2003 Sep; 63(17):5538-43. PubMed ID: 14500392
[TBL] [Abstract][Full Text] [Related]
3. Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport.
Zeng H; Chen ZS; Belinsky MG; Rea PA; Kruh GD
Cancer Res; 2001 Oct; 61(19):7225-32. PubMed ID: 11585759
[TBL] [Abstract][Full Text] [Related]
4. ABCG2 harboring the Gly482 mutation confers high-level resistance to various hydrophilic antifolates.
Shafran A; Ifergan I; Bram E; Jansen G; Kathmann I; Peters GJ; Robey RW; Bates SE; Assaraf YG
Cancer Res; 2005 Sep; 65(18):8414-22. PubMed ID: 16166320
[TBL] [Abstract][Full Text] [Related]
5. Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system.
Chen ZS; Lee K; Walther S; Raftogianis RB; Kuwano M; Zeng H; Kruh GD
Cancer Res; 2002 Jun; 62(11):3144-50. PubMed ID: 12036927
[TBL] [Abstract][Full Text] [Related]
6. Lack of an effect of breast cancer resistance protein (BCRP/ABCG2) overexpression on methotrexate polyglutamate export and folate accumulation in a human breast cancer cell line.
Rhee MS; Schneider E
Biochem Pharmacol; 2005 Jan; 69(1):123-32. PubMed ID: 15588721
[TBL] [Abstract][Full Text] [Related]
7. Transport of amphipathic anions by human multidrug resistance protein 3.
Zeng H; Liu G; Rea PA; Kruh GD
Cancer Res; 2000 Sep; 60(17):4779-84. PubMed ID: 10987286
[TBL] [Abstract][Full Text] [Related]
8. The effect of low pH on breast cancer resistance protein (ABCG2)-mediated transport of methotrexate, 7-hydroxymethotrexate, methotrexate diglutamate, folic acid, mitoxantrone, topotecan, and resveratrol in in vitro drug transport models.
Breedveld P; Pluim D; Cipriani G; Dahlhaus F; van Eijndhoven MA; de Wolf CJ; Kuil A; Beijnen JH; Scheffer GL; Jansen G; Borst P; Schellens JH
Mol Pharmacol; 2007 Jan; 71(1):240-9. PubMed ID: 17032904
[TBL] [Abstract][Full Text] [Related]
9. The role of multidrug resistance efflux transporters in antifolate resistance and folate homeostasis.
Assaraf YG
Drug Resist Updat; 2006; 9(4-5):227-46. PubMed ID: 17092765
[TBL] [Abstract][Full Text] [Related]
10. Mutant Gly482 and Thr482 ABCG2 mediate high-level resistance to lipophilic antifolates.
Bram E; Ifergan I; Shafran A; Berman B; Jansen G; Assaraf YG
Cancer Chemother Pharmacol; 2006 Dec; 58(6):826-34. PubMed ID: 16612649
[TBL] [Abstract][Full Text] [Related]
11. The human multidrug resistance protein MRP5 transports folates and can mediate cellular resistance against antifolates.
Wielinga P; Hooijberg JH; Gunnarsdottir S; Kathmann I; Reid G; Zelcer N; van der Born K; de Haas M; van der Heijden I; Kaspers G; Wijnholds J; Jansen G; Peters G; Borst P
Cancer Res; 2005 May; 65(10):4425-30. PubMed ID: 15899835
[TBL] [Abstract][Full Text] [Related]
12. Methotrexate cross-resistance in a mitoxantrone-selected multidrug-resistant MCF7 breast cancer cell line is attributable to enhanced energy-dependent drug efflux.
Volk EL; Rohde K; Rhee M; McGuire JJ; Doyle LA; Ross DD; Schneider E
Cancer Res; 2000 Jul; 60(13):3514-21. PubMed ID: 10910063
[TBL] [Abstract][Full Text] [Related]
13. The nature of amino acid 482 of human ABCG2 affects substrate transport and ATP hydrolysis but not substrate binding.
Ejendal KF; Diop NK; Schweiger LC; Hrycyna CA
Protein Sci; 2006 Jul; 15(7):1597-607. PubMed ID: 16815914
[TBL] [Abstract][Full Text] [Related]
14. Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions.
Breedveld P; Zelcer N; Pluim D; Sönmezer O; Tibben MM; Beijnen JH; Schinkel AH; van Tellingen O; Borst P; Schellens JH
Cancer Res; 2004 Aug; 64(16):5804-11. PubMed ID: 15313923
[TBL] [Abstract][Full Text] [Related]
15. Characterization of drug transport, ATP hydrolysis, and nucleotide trapping by the human ABCG2 multidrug transporter. Modulation of substrate specificity by a point mutation.
Ozvegy C; Váradi A; Sarkadi B
J Biol Chem; 2002 Dec; 277(50):47980-90. PubMed ID: 12374800
[TBL] [Abstract][Full Text] [Related]
16. A functional study on polymorphism of the ATP-binding cassette transporter ABCG2: critical role of arginine-482 in methotrexate transport.
Mitomo H; Kato R; Ito A; Kasamatsu S; Ikegami Y; Kii I; Kudo A; Kobatake E; Sumino Y; Ishikawa T
Biochem J; 2003 Aug; 373(Pt 3):767-74. PubMed ID: 12741957
[TBL] [Abstract][Full Text] [Related]
17. Single amino acid (482) variants of the ABCG2 multidrug transporter: major differences in transport capacity and substrate recognition.
Ozvegy-Laczka C; Köblös G; Sarkadi B; Váradi A
Biochim Biophys Acta; 2005 Feb; 1668(1):53-63. PubMed ID: 15670731
[TBL] [Abstract][Full Text] [Related]
18. Membrane cholesterol selectively modulates the activity of the human ABCG2 multidrug transporter.
Telbisz A; Müller M; Ozvegy-Laczka C; Homolya L; Szente L; Váradi A; Sarkadi B
Biochim Biophys Acta; 2007 Nov; 1768(11):2698-713. PubMed ID: 17662239
[TBL] [Abstract][Full Text] [Related]
19. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.
Shi Z; Peng XX; Kim IW; Shukla S; Si QS; Robey RW; Bates SE; Shen T; Ashby CR; Fu LW; Ambudkar SV; Chen ZS
Cancer Res; 2007 Nov; 67(22):11012-20. PubMed ID: 18006847
[TBL] [Abstract][Full Text] [Related]
20. Impact of abcc2 [multidrug resistance-associated protein (MRP) 2], abcc3 (MRP3), and abcg2 (breast cancer resistance protein) on the oral pharmacokinetics of methotrexate and its main metabolite 7-hydroxymethotrexate.
Vlaming ML; van Esch A; van de Steeg E; Pala Z; Wagenaar E; van Tellingen O; Schinkel AH
Drug Metab Dispos; 2011 Aug; 39(8):1338-44. PubMed ID: 21566011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
